You’re Still Doing the Work. You’d Like Your Waist to Show It.

Maybe it’s the shirt.

It still fits across your shoulders. But you button it, notice the pull around your middle, and spend a moment deciding whether to leave it untucked.

You trained this morning. You made time for it before the day got away from you. Yet here you are, negotiating with a shirt.

If you’re in your 40s or 50s and still making an effort, that can be the frustrating part. You know what consistency costs. The earlier alarm. The workout squeezed between other things. The fairly sensible meal when you’d have preferred something else.

You’d like some of that effort to show up around your waist. And you’d like to get dressed without giving the whole subject another five minutes.

Then you hear about tesamorelin, a peptide that stimulates your body to release growth hormone. ^[1]

A different signal inside the body. Could that change the fat you’ve been trying to lose?

There is human research behind that question. In one small study of adults with abdominal obesity and reduced growth-hormone release, deeper abdominal fat and waist measurements changed without a significant difference in body weight. ^[2]

Less around the waist, and the scale barely moved?

That’s where this gets interesting. First, we need to get clear on what changed—and whose body it changed in.

Why the growth hormone idea gets your attention

Growth hormone comes from the pituitary, a small gland at the base of the brain. The body releases it in bursts. Its output generally declines with age, which helps explain why it enters conversations about changing body composition. ^[3]

If staying in shape feels more complicated than it used to, you can see the appeal of that explanation. Perhaps there is another part of the picture worth understanding.

Tesamorelin imitates a signal that prompts growth-hormone release. That pathway affects fat breakdown and raises IGF-1, another growth-related signal. It stimulates hormone release rather than supplying growth hormone itself. ^[1]

That distinction is the reason to investigate it. The next question is what happens beyond the hormone measurement.

Age also belongs in context. Body fat, sleep, and fitness are related to growth-hormone output, too. Researchers still debate how much declining GH causes the changes associated with aging. Your birthday and your waistband cannot diagnose a deficiency. ^[3]

So let’s follow the part researchers can measure.

Belly fat is doing a lot of work in that phrase

When you say belly fat, you may mean whatever is changing the fit of your clothes. A study has to be more specific.

There is fat just under the skin, called subcutaneous fat. There is also visceral fat, deeper inside the abdomen around internal organs. Those are different places to store fat, and a treatment’s effect on one does not establish the same effect on the other. ^[4]

A tighter shirt cannot tell you how much of each you have. That is why the tesamorelin studies use measurements such as abdominal scans, rather than asking the mirror to supply the answer. ^[5]

Our recent article on tesamorelin and ipamorelin explains why their evidence deserves separate attention. Tesamorelin has an approved prescription use in the U.S. for excess abdominal fat in adults with HIV-associated lipodystrophy. Its label specifically excludes general weight-loss management. ^[1]

That is an established use. It also leaves a question for the man reading this over breakfast: has anyone studied a situation closer to mine?

A smaller study takes the question beyond HIV

A 2012 randomized trial studied 60 adults with abdominal obesity and reduced growth-hormone secretion. It lasted 12 months. This was a selected group, not people enrolled simply because they had reached middle age. ^[2]

Their average age was about 41, and 39 were men. Only 36 of the 60 completed the full year, which is an important limit when interpreting a small study. ^[5]

Tesamorelin reduced scan-measured visceral fat compared with placebo. Waist circumference fell by an average of about 2 centimeters in the treatment group, while it rose by about 1 centimeter with placebo. Body weight and abdominal fat just under the skin did not change significantly between groups. ^[2]

A modest waist change over a year. A measurable difference in deeper fat. A scale that missed part of the story.

That gives the interest in tesamorelin something concrete to rest on. It also gives you a much better question to ask than whether a peptide is simply good for fat loss.

A larger, earlier trial studied 412 adults with HIV and abdominal-fat accumulation. After 26 weeks, measured visceral fat had fallen 15.2% with tesamorelin and risen 5.0% with placebo. Those percentages describe that fat compartment in that population. They are not percentages of total body weight. ^[6]

The studies give us a reason to take the molecule seriously. Whether their findings fit your health, your starting point, and the change you want takes another step.

What would count as progress for you

Maybe you’d happily keep the same number on the scale if your clothes felt more comfortable and you could keep enjoying your training.

That is a useful goal to say out loud. It makes the decision more specific. You care about where change happens, how you feel, and what the plan asks of your life.

You may want a smaller waist, better strength, or improved health measures. Those goals need their own evidence. A change in one abdominal-fat measurement cannot answer every question about the body around it.

Our latest tesamorelin report explores why a change on a scan and a change in everyday physical ability need separate tests.

Sleep deserves space in that plan, too. In a small crossover experiment, ten adults on a reduced-calorie diet lost less fat and more fat-free mass when they had less time available for sleep. That term includes more than muscle. Our piece on sleep and muscle recovery explains what the short experiment can—and can’t—tell us. ^[7]

If you’re making room for workouts in a crowded week, ask what will show you the plan is working—and whether you can live with the routine long enough to find out.

Your own growth hormone still comes with tradeoffs

The phrase your own growth hormone is appealing. It can also make a medical treatment sound simpler than it is.

Tesamorelin can raise blood sugar and IGF-1, cause fluid retention or joint symptoms, and produce injection reactions. Active cancer and certain problems affecting the brain–pituitary hormone pathway rule out its use. Long-term cardiovascular safety remains uncertain. Those are reasons for a qualified clinician to assess the exact treatment and your medical history. ^[1]

There is a practical question, too: how long would the benefit need treatment to continue? In a follow-up to the larger HIV trial, participants who switched from tesamorelin to placebo regained visceral fat. It was not a permanent reset after a short course. ^[8]

If the point is a change you can sustain, the injections, monitoring, and ongoing commitment belong in the decision from the start.

You can be interested in the mechanism and still want clear answers about the life that comes with using it.

Make the next question specific

For a man watching his waist change in midlife, tesamorelin is worth understanding because its research connects a hormone signal with measured changes in abdominal fat. That is a more useful starting point than a promise to make you younger.

Start with our tesamorelin research comparison. It explains the approved use, how the evidence differs from ipamorelin’s, and why the exact product matters.

Then bring a qualified clinician the question you actually need answered: My waist is changing, I’m still training, and I want to understand what would help—and how we would measure it.

That leaves room to examine the causes, compare established options, and decide whether the tesamorelin research has any bearing on your situation.

You’d like to pull on the shirt and think about the day ahead. Keep that ordinary, very human goal in the conversation.

Sources

1. EGRIFTA WR tesamorelin prescribing information. DailyMed / Theratechnologies. Updated July 29, 2026; prescribing information revised March 2025.
2. Metabolic Effects of a Growth Hormone-Releasing Factor in Obese Subjects with Reduced Growth Hormone Secretion: A Randomized Controlled Trial. Makimura et al. The Journal of Clinical Endocrinology & Metabolism. 2012. NCT00675506.
3. Hormones and Aging: An Endocrine Society Scientific Statement. Endocrine Society / The Journal of Clinical Endocrinology & Metabolism. 2023.
4. Obesity and Cancer Fact Sheet. National Cancer Institute.
5. Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese. ClinicalTrials.gov. NCT00675506.
6. Metabolic effects of a growth hormone-releasing factor in patients with HIV. Falutz et al. New England Journal of Medicine. 2007.
7. Insufficient sleep undermines dietary efforts to reduce adiposity. Nedeltcheva et al. Annals of Internal Medicine. 2010.
8. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. Falutz et al. AIDS. 2008.

Editorial disclosure: This article was prepared with AI assistance and has not been independently reviewed by a qualified medical or scientific professional. It is educational information, not personalized medical advice.